Table 1.
Baseline clinical characteristics in 149 HBsAg-positive cervical cancer patients.
| Variables (n = 149) | |
|---|---|
| FIGO staging system, n (%) | |
| I | 50 (33.6) |
| II | 68 (45.6) |
| III | 27 (18.1) |
| IV | 4 (2.7) |
| Lymph nodes metastases, n (%) | |
| No | 94 (63.1) |
| Yes | 55 (36.9) |
| Antiviral therapy, n (%) | |
| No | 125 (83.9) |
| Yes | 24 (16.1) |
| baseline serum AST levels (U/L), n (%) | |
| ≤40 | 133 (89.3) |
| >40 | 16 (10.7) |
| Treatment modality, n (%) | |
| RSA | 20 (13.4) |
| DCRT/RRA | 54 (36.2) |
| RS-CRT/RS-R/C | 45 (30.2) |
| other treatments | 30 (20.1) |
FIGO, International Federation of Gynecology and Obstetrics; AST, aspartate aminotransferase; RSA, radical surgery alone; DCRT/RRA, definitive chemoradiotherapy or radical radiotherapy alone; RS-CRT/RS-R/C, radical surgery combined with chemoradiotherapy or radical surgery combined with radiotherapy/chemotherapy.